CSLLY
CSL LTD
- PER (TTM)
- 14.10
- PER (Forward)
- 11.15
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 2.24
- 시가총액
- 41.59B
- 배당수익률
- 334.00%
- 베타
- 0.14
- 1개월 수익률
- -13.09%
- 3개월 수익률
- -31.53%
- 6개월 수익률
- -23.57%
- 1년 수익률
- -43.64%
- 2년 수익률
- -
- 5일 평균거래량
- 334780
- 60일 평균거래량
- 467250
- 1년 평균거래량
- 304219
- 5d/60d 거래량 비율
- 0.72×
- 60d/1y 거래량 비율
- 1.54×
- 변동성(60일, 연환산)
- 30.23%
- BB 스퀴즈 스코어
- 1.26
- SMA50 비율
- 0.90
- SMA200 비율
- 0.72
- RSI (14)
- 33
- 20일 수렴도
- 0.05
- 52주 최고
- 43.94
- 52주 최저
- 21.71
- 고점 대비
- -50.59%
- 저점 대비
- 0.00%
펀더멘털 갱신: 2026-05-10T08:29:06+00:00 · 시세 갱신: 2026-05-10T06:21:30+00:00
회사 정보
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.